Who Makes Mounjaro, and How Does It Reach UK Patients?

How Eli Lilly brought tirzepatide from the lab to a licensed UK medicine

Eli Lilly's scientists began exploring dual gut-hormone agonism as a therapeutic approach in the 2010s, reasoning that activating both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor together might outperform medicines acting on either receptor alone. That hypothesis proved correct. The resulting molecule, tirzepatide, was studied across the large SURMOUNT clinical programme, and the headline result from SURMOUNT-1, published in the New England Journal of Medicine, was striking: participants taking the 15 mg dose lost an average of around 20 to 21 per cent of their body weight over 72 weeks. That level of efficacy, alongside a well-characterised safety profile, supported Lilly's applications to regulators worldwide. The MHRA granted UK approval, and NICE subsequently recommended tirzepatide for adults with obesity in TA1026, published in December 2024. For a deeper look at the compound itself, the tirzepatide overview page covers the mechanism in more detail.

If you are curious about who makes Mounjaro for weight loss and how the drug's origins connect to its clinical development, that background can help you feel more confident about the medicine you are taking. Mounjaro reaches patients as a pre-filled KwikPen (each pen contains four weekly doses) available in six UK strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Treatment begins at 2.5 mg, a starting point designed to let the body adjust rather than to deliver the full therapeutic effect straight away, and is titrated under prescriber guidance from there.

What the Eli Lilly name on the box actually tells you about sourcing

In the UK, only pharmacies buying from Eli Lilly's authorised wholesale network can legitimately supply Mounjaro. That chain of custody matters. The MHRA has documented a serious and growing trade in counterfeit weight-loss pens sold online and via social media. In October 2025, enforcement teams raided the UK's first illicit manufacturing site producing fake tirzepatide pens, seizing roughly 20 million doses of illegally traded weight-loss medicines with an estimated street value of around £45 million. Fake pens have in some cases contained insulin, with potentially life-threatening consequences.

The practical upshot: if you see Mounjaro offered at prices far below the typical UK market range, or from a seller who cannot point you to a GPhC pharmacy registration, treat that as a serious red flag. You can check any online pharmacy on the GPhC register in under a minute. Sellers operating outside the licensed supply chain are not just harder to trust, they are illegal. You can report a suspect seller to the MHRA at Yellow Card.

For more on what to look for when buying this medicine online, the guide to buying Mounjaro online safely covers the key checks.

Who Mounjaro is licensed for in the UK, and what Lilly's price change meant for patients

The UK licence allows Mounjaro to be prescribed for adults managing their weight (BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea) and for adults with type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. As described in NICE's appraisal of tirzepatide (TA1026), the full clinical picture, not the BMI figure alone, shapes whether treatment is appropriate.

From 1 September 2025, Eli Lilly restructured Mounjaro's UK list price significantly, the highest-dose pen rose from around £122 to around £330 per four-week pen, according to widely reported industry coverage. Private prices across providers have typically ranged from roughly £149 to £375 per month depending on the dose, as a result. That context is worth knowing, not because price should be the deciding factor for a prescription medicine, but because it explains why the numbers you see quoted can vary so much between providers and over time. A fuller picture of what private treatment costs is on the weight-loss treatment overview.

One practical detail many patients ask about: Mounjaro pens are refrigerated between 2 and 8°C. Some patients also notice they feel cold while taking Mounjaro, a side effect worth being aware of before you start treatment. Keeping a pen in the fridge door rather than pushed to the back is a small habit that makes the weekly routine easier, but the exact storage and in-use temperature window is set out in the Patient Information Leaflet, not a detail to rely on from any content page.

Questions about the clinical team behind our prescribing decisions, or the pharmacy that holds these medicines? Our about us page sets out how the service is structured, and you can read about our clinical oversight on the clinical lead's profile page. If something specific isn't answered there, our team is reachable seven days a week. Patients sometimes also want to understand who makes the Mounjaro drug and how it is manufactured, or to explore who makes Mounjaro in broader terms, and both pages go into that detail.